Metabolic intervention with GLP-1 or its biologically active analygues to improve the function of the ischemic and reperfused brain

A glucagon, biologically active technology, applied in the field of improving ischemic and reperfused brain function, can solve insulin complications and other problems

Inactive Publication Date: 2002-10-23
AMYLIN PHARMA INC
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, insulin use is complicated by uncertainties about the neurotoxicity of hyperglycemia, the potential benefits of moderate glycemia, and the lethal potential of severe hypoglycemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0061] According to the present invention, the use of GLP-1 (aminated glucagon-like peptide-1 (7-36)) is an ideal replacement for insulin for the treatment of acute stroke. This is because GLP-1 has a glucose-dependent insulinotropic effect. GLP-1 can promote the secretion of endogenous insulin under normal or hyperglycemic conditions, but not under hypoglycemic conditions, which can prevent severe hypotension. This also means that in type 2 diabetes, GLP-1 can stimulate the continuous secretion of insulin and correct blood sugar in the normal range. These effects will bring great benefits to acute stroke patients. Similar results were obtained in non-diabetic stroke patients with concomitant stress hyperglycemia. In normoglycemic stroke patients, GLP-1 causes a modest secretion of insulin that returns to baseline levels when glucose is not supplemented. In this case, it is best to simultaneously infuse intravenous glucose (low dose, eg 5%) in order to maintain the stimulat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.

Description

field of invention [0001] The present invention relates to an effective treatment for improving ischemic and reperfused brain function. Background of the invention [0002] A stroke, or cerebrovascular accident, is caused by an acute blockage of cerebral blood flow to an area of ​​the brain. With approximately half a million cases per year in the United States, 30% of which are fatal, stroke is thus the third leading cause of death in the United States. Eighty percent of these strokes are "ischemic," which results from an acute embolism (usually a blood clot or thrombus) in a brain artery and a reduction in blood flow. The remaining part is "hemorrhagic", which means that a large amount of blood flows into the brain organ due to the rupture of the cerebral artery, and then the blood flow is blocked due to the contraction of the local tissue, resulting in ischemia. [0003] Stroke usually occurs in individuals over the age of 65, and high blood pressure is the leading risk ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7004A61K38/00A61K38/26A61P9/10
CPCA61K38/26A61P25/00A61P7/00A61P9/10A61K2300/00
Inventor T·R·库利奇M·R·W·埃勒斯
Owner AMYLIN PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap